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The complexity of the events that culndnnte in iotimal prolifera- 
tion aner arterial injury and similsrilien between this response 
and baign neOplasia suggesl (hat ponwmional medical therapies 
will eonlinue to he unsuccessful in preventing wewren stenosis 
after percutaneous eomnary revawdwilstlon. By preventing wll 
division after Smooth muscle elI activation, antimltogwdetherapy 
may inhibit he final commcm pathway in this complex chain of 
events and oBsel the apparent loss of local growth wnlrd. 
Colchicine, which caws metephase arrest of cell division. has 
b+en shuwn in experimental sludies to deerease the extent of 
atheramahntr ~laaue formation and reduce the swerhv of arterial 
low dare colchicine (0.6 mg &vice a day orally) dms not prwen~ 
r&E”MiS. 
The UP of more polenl anGneoplastic agents is limiled by the 
potential for 8fe.threatming side eUeels. It Is pasiblr that these 
adverse eLctr can be averted by using novel drug delivery 
systems Lo administer aotimltogrnic therapy locally at the site of 
arterial iNury or by uslog low dose sywrgistie eombinatiom of 
antiprolilralivepg~nts. This review exmnii;oslhcpotential role01 
antimi@enic therapy in the prevention ai r&en& rftw cow 
nary intwenlions and considers the pasjibility of an overlap of 
the therapeutic realms cd ialerventionel cardmlogy and medical 
OlXol0gy. 
(J An Co11 Cordial 1991;I 7:1268-318) 
Despite intensive cbnical and experimental invesGgation 
over the past decade. the incidence of recurrwt Senosis 
after balloon dilation of coronary anery stewsis has re- 
mained remwkably constant. Allhough several animal stud- 
ies of antiplatelet, anticoagulant and vasodilator therapies 
have reported favorable reductions in the severity of the 
intimal proliferative response lo balloon injury, clinical 
studies (l-4) have failed 10 identify any single pharmacologic 
agent that consistently inhibits this response. More recently, 
attempts have been made to modify the endovascular injury 
inflicted during percutaneous revascularization procedures. 
These &Tons have included the use of dcviccs that excise. 
campress or heat atheromatous tissue and others that use 
laser energy lo ablate obstructive material (5). Preliminary 
data from follow-up studies (6-8) suggest lbal these proce- 
dures may also he associated with an incidence of restenosis 
that is comparable with that of conventional balloon angio- 
plasty. Moreover, histologic analyses (9.10) have suggested 
that the intimal proliferative response after these dissimilar 
injuries may he pathologically indistinguishable from the 
response to balloon dilation. These findings suggest a limited 
role for further modiiicatwn cf the nature of the anerial 
injury. 
;.ar this reason, akhough tnese new devices remain a 
valuable means of o$imizing the initial pmcedural result 
(II). the focus of attention for many investigators has 
returned to the evaluation of pharmacologic preventive 
measures. The agents currently under experimemal investi- 
gation include a variety of antineoplastic drugs. The use of 
such potent therapies has arisen from the recognition I) of 
the complexity of the factors that lead lo smooth muscle cell 
activation, and 2) of parallels between the smooth muscle 
cell proliferative response of restenosis and the apparently 
unrestricted growth of neoplastic cells. 
Stimuli to Intimal Proliferation 
The complexity of the vascular reparative response 10 
injury has been well reviewed by several inves@tors 
(12-14). If now appears clear that multiple heterogeneous 
faclon trigger a common response lo injury (Fig. I). This 
response consists of medial smooth muscle cell activation 
characterized by a change in smwth muscle cell phenotype 
from contractile lo synthetic form, migration of both pheno- 
typos from Lhe arterial media to the intima, exuberant 
smooth muscle cell proliferation and subsequent synthesis 
and secretion of extracellular collaw~~~s matrix (H-17). In 
some individuals, this process co&ues, apparently unim- 
peded by normal control mechanisms, until the neointima 
encroaches on the arterial lumen and compromises coronary 
Figure 1. Stimuli to smwth muscle cell ISMCI proliferatmn after 
arterial wall iniurv. The vascular eoaratwc resnonse mav be 
triggered by n&h&al factors, eleme& of the co&latian s&m 
and the inflammatory esponse and changer in blood Row. 
flow. The growth factors that trigger this response. including 
platelet-derived growth factor. fibroblast growth factor. epi- 
denoal growth factor. transforming growth factor (I and 
insulin-like growth factor, are released from activated plate- 
lets, otooocytes. endothelial cells and smooth muscle cells 
themselves. In addition, ntmwoos other components re- 
leased after arterial trauma. including endothelin 118). inter- 
leukin-I (19) and leukotriene B4 (20). have been shown to 
promote medial smooth muscle cell proliferation. Other 
factors, including stretch alone (21). may activate smooth 
muscle cells indirectly by inducing the formation of growth 
factor receptors (U) or directly by provoking the autocrine 
release of growth factors from smooth muscle cells them- 
selves (23). 
Whereas conventional medical approaches to the preven- 
tion of restenosis have attempted to inhibit individual com- 
ponents of this response. newer approaches may include 
inhibition of the induction and expression of smooth muscle 
cell growth factor receptors and interference with intracel- 
lulx~signal hansduct& Less futuristic. perhaps. is the 
possibility that antimitogenic therapy may inhibit the final 
common bathway by pr&eoting &dial s&&h muscle cell 
division and proliietation. Whether it is also necessary to 
prevent migration and collagen synthesis by nonproliferating 
smooth muscle cells is at present unknown. 
Intimal Proliferation and Neaplasia 
A second argument for the evaluation of antineoplastic 
therapy in this context is the analogy between intiotal 
pmliferatian and benign neoplasia. In 1973, a pathologic 
study (24) of atherosclerotic lesions in black women who 
were heterozygous for glucosed-phosphate dehydrogenase 
suggested that individual plaques were composed of cells 
that were monoclonal in origin. This raised the possibility 
that the underlying pathogen.% of atherosclerosis is focal 
neoplasia (24). Subsequent investigations (Zs) have bLen 
inconsistent in supparting or refuting this concept. An even 
closer analog to the intimal omliferatlon of restenosis may 
be the f&&n of k&id scan from abnormal *.vounb 
healing in zeenetically sosceotible individuals. These benian 
dermal tumors have reduceh growfh factor requirements% 
cell colture and respond differently from unaffected skin to 
exogenous growth factors (261. These differences have been 
attributed to the automine production of growth factors by 
dcrmal cells. reduce production of growth-inhibitory pep 
tides or alterations m growth factor receptor activity or 
postreceptor signal transduction (26). 
It is clear from tritiated thymidioe studies that experimen- 
tally induced intimal proliferative lesions and. presumably. 
the lesions of coronary restenosis after balloon dilation are 
not of monoclonal origin. The cells of these lesions may. 
however, have altered growth characteristics and responses 
to mitogens when compared with cells from primary athero- 
sclerotic lesions. lo a recent study by Dansch et al. (27). 
cultured human smooth mu& cells obtained from atherec- 
tomy of recurrent femoral attery steooses shinved a sigoift- 
cantly higher baseline growth rate and a heightened prolif- 
erative response to platetetdaived growth factor and agrowth 
factor mixture isolated from bovine brain when compared with 
cells derived from advanced primary steooses. 
Perhaps one of rhc most intrigr,ing similoriries herween 
rerrenosis and nroplusin ir the apparen! homology berween 
plot&r.deriwd growfh factor and mitogens released from 
vmlignanr ne~plasms. A striking stnc~uml. functional and 
immunologic homology has been noted. for example. be. 
tween platelet-derived growth factor and p28-. the trans- 
forming protein of the simian sarcoma virus (28). and a 
similar mitoeen has been purified from human osteosarcoma 
cells. Human astrocytomas have also been shown to express 
both platelet-derived growth factor and its receptor genes. 
suggesting that platelet-derived growth factor may act as a 
potent protcxmcogeoe in the maintenaoce of gmwh of these 
twoors 129). 
Thr unulvgy bcrween coronary resrrnosh and focal be- 
nian smoolh mrrscle cell nioploxia with failure of normal 
growth ron~rol mechanisms is, therefore, an attractive, if 
somewhat simplistic concept. Indeed. the term “malignant 
restenosis” has recently found its way into the lexicon of 
interventional cardiologists to describe the frustratingly 
rapid and mtractable recorreoce ofcoroaary artery stenoses 
after a variety of percutaneous coronary interventions. With 
these considerations in mind, is there a role for antimitogenic 
therapy in the prevention of restenosis after balloon aogia- 
plasty? Two classes of antimitogenic agents (colcbicine and 
the antineoplastic agents) warrant evaluation. 
Cokbkine 
Merhnnurn ol act&m. Cakhicine is an alkaloid derived 
from the slant Colchicbtm osrronnob. Its medicmal use was 
described as early as the Is1 century AD and its principal 
mechanisms of action were described in 1889 by Pemice (30) 
and later evaluatedindetail by Taylor (31). It binds with high 
Figure 1. Phases of the cell cycle. Cokhicinc binds to mmotubular 
protein. resulting in metaphase arrest. Methotrcxate inhibits DNA 
synthesis 67 phase) by prewning the formation of tetrahydrofolate. 
allinity to tubulin. the subunit protein of microtubules. 
thereby inhibiting the assembly of these organelles and, to a 
variable extent. causing disassembly of microtubules that 
have already been formed. Because normal microtubule 
function is essential for spindle formation, colchicine ther- 
apy results in me&phase arrest of cell division (Fig. 2). In 
addition, colchicine inhibits other microtubuledependent 
functions, including the secretion of polymorphonuclear cell 
and monocyte chemotactic factors (32.33). the synthesis and 
secretion of collagen (34) and ~ysosonte degranulation after 
phagocytosis (30). Furthermore, colchicine therapy has been 
shown to increae collagenase activity (35) and inhibit plate- 
let aggregation and secretion (36). Its principal therapeutic 
use has been in the treatment of acute gouty arthritis and as 
prophylactic maintenance therapy for hyperuricemia. 
The anti-inflammatory and antifibrotic activity ofthe drug 
have prompted its evaluation in several nonrheumatologic 
conditions. In a recent randomized clinical trial of patients 
with hepatic cirrhosis (37), colchicinc therapy wns nssoci- 
ated with a reduction in the severity and extent of periportal 
inflammation and fibrosis and an increase in long-term sur- 
vival. Colchicine has also been used us an nntineoplastic 
agent for malignant conditions, including acute leukemia. Its 
use for these conditions has been limited, however, by a high 
incidence of side etfects, including hemorrhagic gastroenteri- 
tis and bone marrow depression. None!heless, its broad 
spectrum of antiprolifcrative, anti-inflammatory and antifi- 
brotic activity suggests a potenrial role for colchicine in the 
prevention of restenosis after percutaneous coronary revas- 
cularization procedures. 
Ex&nental studies nf cokhirine and vascular injury. 
This possibility is supponed by a small number of experi- 
mental studies. Colchicine has been shown to inhibit to a 
variable extent the development of atherosclerotic plaques 
in several animal models (38-40). Hollander et al. (38), for 
example. showed a reduction in the severity of visible antic 
atherosclerosis in rabbits fed an atherogenic diet. The le- 
sions that developed in the treated animals contained less 
free and ester cholesterol and less collagen and elastin than 
did the lesions of rabbits fed an athcrogenic diet alone. 
Similarly, in rabbits with established atherosclerosis (39), 
colchicine therapy during a subsequent hypocholesterolemic 
Figure 3. ERect ofhigh and low dose colchicine on restenosis in the 
atherosclerotic rabbit iliac artery model. Data adapted from Currier 
et rd. ,411. 
regression diet appeared to reduce the severity of intimal 
fibrous tissue formation. Only one study (41) reponed the 
use of colchicine to prevent intimal thickening after balloon 
arterial injury. In the atherosclerotic rabbit model, Currieret 
al. (41) showed n moderate reduction in the severity of 
restenosis 4 weeks after iliac arterial balloon dilation in 
animals treated with high dose (0.2 mgntg per day) but not 
low dose (0.02 m&g per day) colchicine (Fig. 3). It should 
be noted, however, that the chronic high dose colchicine 
therapy used in this study would rdmo~t certainly not be 
tolerated in clinical studies. 
Clinical restenusis trials. Low dose colchicine therapy 
was recently evaluated in a randomized placebo-controll&l 
clinical trial at the Mid-America Heart Institute (42). The 
majority of the 197 patients enrolled in the study had 
multilesion or multivessel disease and approximately SO0 
coronary stenoses were dilated. Patient~~were radomly 
assigned to receive colchicine (0.6 mg twice a day orally) or 
placebo commencing on the day before the angioplasty 
procedure and continuing throughout the study period. Drug 
efficacy was evaluated with use of exercise thallium scint’g. 
raphy 3 months after the procedure and repeat eorotory 
angiography at 6 months. Although this low dose therapy 
was reasonably well tolerated in the majority of patients, 
adverse effects requiring termination of drug therapy oc- 
curred in approximately 7% of the treated patients. In a 
nreliminarv analvsis of the data from the first 145 natients 
completing the study, the incidence ofrestenosis at Btuonths 
was 46% in the colchicine-treated group compared with 47% 
in the placebo group (p = NS). 
Antineoplastic Therapy 
Experimenlal studies. The use of more potent antimito- 
genie agents for the prevention of restenosis has not been 
well studied, predominantly because of the potential hazards 
of such toxic therapy and the relatively benign clinical 
consequences of restenosis. The agents used most fre- 
quently to treat malignancies of mesenchymal cell origin 
include vincristine, actinomycin D, doxorubicin. cyclophos- 
Figure 4. The oxmary infusion balhwn catheter. Drug is delivered 
directly into the arterial wall through a series of 25 pm diameter 
haies. Reproduced with permission fmm Wolinksy and Thung (45). 
phamide and methotrexate. A regimen of combined low dose 
intravenous vincristine (0.075 mdkg) and actinomycin D 
(0.015 “g/kg) was recently evaluated in a rabbit model of 
aortic endothelial injury (43). Three days after endothelial 
denudation. the animals treated with antineoolastic theraov 
had fewer subintimal smooth muscle cells’(l55% YE& 
223% of the contra! number) and less evidence of activation 
(nuclear euchromatization gnd endoplasmic reticular con- 
tent) by electron microscopy when compared with the con- 
trol untreated animals. Whether this thenpy has any impact 
on the degree of subsequent intimal thickening in this model 
is unknown because longer-term studies were not reported. 
Loeyl drug d&very at site of aneioploscr. A more accept- 
able approach to the systemic admioistration of potentially 
Me-threatening drug therapy to patients with nonmalignant 
conditions may be local drug delivery at the site of balloon 
angioplasty. We investigated the use of the antimetubolite 
methotrexate given locally for the prevention of intimal 
proliferation after bal1oo.1 arterial injury in the porcine 
carotid artery model (44). Methotrexate is a competitive 
inhibitor ofdihydrofokue reductase, the nzyme responsible 
for the synthesis of tetrahydrofolate from dihydrofolate. 
Inhibition of the enzyme results in a cellular deficiency of 
tetrahydrofolate, a compound essential for the synthesis of 
pmines and pyrimidines and thus for the synthesis of deoxy- 
ribonucleic acid (DNA) and ribonucleic acid (RNA). Cellular 
proliferation is therefore prevented by inhibition of the S 
phase of the cell cycle (Fig. 2). Unlike most antineoplastic 
agents. the elTects of methotrexate can be rapidly reversed 
with high dose folinic acid (5.formyl tetrahydrofolate) res- 
cue. For this study, the drug was delivered through a 
specially designed infusion catheter. The catheter has a 4.3F 
triple lumen shaft with u distal balloon made of polyethylene 
tetraphthalate. The balloon has 28 holes. 25 rm in diameter, 
in longitudinal rows (Fig. 41. In a previous study (45) 
evaluating this balloon, Ruoresceinated heparin delivered at 
5 atm pressure for I min penetrated the full thicknas of a 
canine arterial wall and remained detecrable for 48 to 72 h. 
After balloon angioplasty bilateral carotid angioplasty 
was performed by direct cutdown under general anesthesia 
in IS Yucatan minipigs (46). In IO of these animals. meth- 
otrcxate 16.25 mg!mlJ was then infused locally at the site of 
balloon dilation in one carotid artery. The contralateral side 
was infused with 0.9% saline solution. The local administra- 
tion of methotrexate did. in fact. result in transient low 
therapeutic systemic drug levels ranging from 0.7 to 
22 &liter (therapeutic range IO to LOCOJ. Because the 
contralateral side WIE exposed. if only transiently, to circu- 
lating methotrexate. five additional animals underwent ~a. 
mid angioplasty and bilateral infusion of saline solution as 
“Irue” control animals. Tritium-labeled methotrexate wan 
used to determine the dumtion of local drug effect. The 
intramural drug concentration in the treated carotid anery at 
the site of balloon injury was I .0@3-fold greater than the 
serum concentration 2 h after drug administtaion and very 
high tissue cowxntrations were maintained for t7 days. 
After the surgical procedure, each animal *as maintained on 
B normal diet for 4 weeks. at which time it was killed and the 
carotid arteries were resected for histologic analysis. 
Pr&ninaq darn from this study f&J su~.ear that de 
inrimal proliferative respoustse is nor obo/&~and may not 
even be attenuated using this dose of methotrexate and this 
delivery system. :‘:betber the drug itself is ineffective or the 
duration of hs activity is inadequate with this approach ih 
unclear at present and is the subject of ongoing avestigation. 
Other app’orba. The potential role of long-term local 
drug delivery at the site of arterial dilation is the focus of 
intense research in several academic centers. Other drug 
delivery systems that may prove to be valuable include 
drug-impregnated polymer-coated metallic stents. biode- 
gradable drug-eleing polymer stems (47) and genetically 
primed endothclial cells to coat metallic stews i48J or be 
delivered directly as P local endothelial cell covering (49). 
These systems may allow the safe use of potent antiprolif- 
erative therapies. including antimitogenie agents. in high 
local concentrations without systemic side etTects. 
Several other approaches warrant further invesrigotion. 
It may be possible. for example. to find synergistic drug 
combinations to inhibit intimal proliferation. Low dose an- 
limitogenii therapy given orally or parenterrdly for a period 
of 7 to IO days may be adequate well tolerated therapy if 
combined with a patent growth factor antagonist. Altema- 
lively. because a substantial propo&n of the wointima is 
comwsed of collaaenous matrix (some of which may be 
deri&d from nonp&iferating cells). the combination of an 
antineoplastic agent with a powerful inhibitor of collagen 
formation may be valuable. 
COllCiUSions 
On purely theoretic grwods. antimitogenic therapy ap 
pears to offer some potental as an lpproach to the preven- 
tion of restcnoss. Its use may b-e limited, however, cat only 
by troublesome systemic side ffects. but also by the poten- 
tially deleterious effects of inhibition of regrowth of the 
endothelium. Conceivably. the latter e&ct may actually 
increase the seventy of restenos~r by prolonging the period 
of exposure of subintimal tissue. If lhese therapies do prove 
10 he successful in reducing the incidence of restenosis. 
consider&m will need to be given to patient selection 
criteria for vestment because approximately two thirds of 
patients undergoing their first percutaneous revasculariza- 
lion procedure do not develop recurrent stenosis. One 
possible mans of identifying individuals at particularly high 
risk of restenosis may be the examination of material oh- 
tained by coronary atherectomy t9.10.27). In much the same 
way a biopsy of a neopiastic growth CRD provide informa- 
tion regarding its activity and growth potential, endovascular 
biopsy using an alherectomy device may give useful infor- 
mation about the probability of subsequent restenosis. Thia 
possibility is the subject of ongoing research at our institu- 
tion. 
From what is known about the pathologic response to 
balloon sngioplasty and related interventions. it 6eerns likely 
that a combined mechxical and pbxmacologic approach 
will be necessary to optimally treat coronary stenosis and 
prevent subsequent restenosis. Whether the pharmacologic 
component of that therapy should be drugs as potentially 
toxic as the antineaplasric agents is at present unclear. 
Further evalualion of these agents in experimental models of 
restenosis seems warranted, however, because this may at 
the very least provide valuable insights into the patbogenesis 
of this highly complex process. 
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